Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 4/20 | 0.46 |
| ▸ | RAF1 | P04049 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989083 | 0.83 | MAPT (0.55) | MAPTGSK3BBRAFRAF1SMN1; SMN2 | |
| SCHEMBL27866914 | 0.79 | MAPT (0.51) | MAPTGSK3BBRAFRAF1SMN1; SMN2 | |
| SCHEMBL18247723 | 0.76 | L3MBTL1 (0.53) | MAPTSMN1; SMN2RAB9ATP53NPC1 | |
| SCHEMBL3542778 | 0.76 | CHRNB4 (0.44) | — | |
| SCHEMBL3542780 | 0.76 | CHRNB4 (0.44) | — | |
| SCHEMBL790400 | 0.75 | PI4KA (0.48) | MAPTJAK2BRAFRAF1ALDH1A1 | |
| SCHEMBL17602322 | 0.74 | MAPT (0.45) | MAPTGSK3BSMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL12205229 | 0.73 | LRRK2 (0.51) | MAPTSMN1; SMN2RAB9ATP53NPC1 | |
| SCHEMBL2088657 | 0.71 | JAK2 (0.47) | MAPTJAK2SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL18247763 | 0.70 | L3MBTL1 (0.44) | MAPTSMN1; SMN2RAB9ATP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | MAPT 3291/4885GSK3B 512/4885JAK2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.